Advisors Preferred, LLC Halozyme Therapeutics, Inc. Transaction History

Advisors Preferred, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$37.81 - $52.4 $2.74 Million - $3.8 Million	72,463 Added 291.64%	97,310 $5.1 Million
Q1 2024 May 08, 2024	BUY	$33.68 - $41.95 $836,846 - $1.04 Million	24,847 New	24,847 $1.01 Million
Q4 2022 Feb 08, 2023	SELL	$40.06 - $59.44 $53,119 - $78,817	-1,326 Reduced 16.73%	6,602 $375,000
Q3 2022 Nov 07, 2022	SELL	$38.53 - $51.78 $5,047 - $6,783	-131 Reduced 1.63%	7,928 $317,000
Q2 2022 Aug 11, 2022	SELL	$37.35 - $48.3 $107,530 - $139,055	-2,879 Reduced 26.32%	8,059 $355,000
Q1 2022 May 09, 2022	BUY	$31.97 - $41.06 $349,687 - $449,114	10,938 New	10,938 $455,000
Q2 2021 Jul 26, 2021	SELL	$38.84 - $51.31 $2.65 Million - $3.5 Million	-68,276 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$39.51 - $51.45 $1.16 Million - $1.51 Million	29,299 Added 75.17%	68,276 $2.9 Million
Q4 2020 Feb 03, 2021	BUY	$25.81 - $43.62 $1.01 Million - $1.7 Million	38,977 New	38,977 $1.65 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Advisors Preferred, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisors Preferred, LLC with notifications on news.